首頁 > 市場調查報告書 > 醫療設備

體外診斷液體活檢

市場調查報告書

商品編碼

1297809

全球液體活體組織切片市場 - 2023-2030年

Global Liquid Biopsy Market - 2023-2030

出版日期: 2023年06月15日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球液體活體組織切片市場在2022年達到41億美元，預計到2030年將見證有利可圖的成長，達到123億美元。在2023-2030年的預測期內，全球液體活體組織切片市場預計將呈現15.4%的複合成長率。

液體活體組織切片是一種非侵入性的診斷技術，可以分析體液中的生物標記，提供對各種疾病（如癌症）的洞察力。與傳統的組織活體組織切片相比，它具有優勢，如更容易收集樣本和即時監測疾病。

此外，全球癌症發病率的增加，基因組研究和技術的進步，擴大採用微創診斷程序，以及早期檢測和監測疾病的潛力上升，預計將在預測期內推動市場發展。

市場動態

對患有實體癌的兒童進行液體活體組織切片的研究不斷增加，預計將推動液體活體組織切片市場的成長

根據美國國家癌症研究所2023年的文章，癌症領域的研究人員正在液體活體組織切片測試的開發方面取得進展，這有可能補充甚至取代傳統的組織活體組織切片。

這些測試分析腫瘤釋放到血液和其他體液中的遺傳和其他物質。目前，液體活體組織切片被用來檢測與癌症有關的基因改變，並幫助治療決策。

科學家們已經將液體活體組織切片的研究範圍擴大到了癌症兒童，重點是實體瘤，如尤因肉瘤、骨肉瘤和威爾姆斯瘤（一種腎癌）。洛杉磯兒童醫院（CHLA）和南加州大學的研究人員最近進行的一項研究在開發專門針對兒童癌症患者的液體活體組織切片測試方面取得了進展。

這種測試分析了在血液樣本中發現的DNA片段，並在診斷兒童的各種類型的實體腫瘤方面顯示出有希望的結果。發表在《npj Precision Oncology》上的這項研究還表明，這種檢驗在評估治療反應和檢測成功的初始治療後可能的腫瘤復發方面具有潛力。

CHLA和南加州大學的研究人員開發的液體活體組織切片檢驗側重於使用低通量全基因組測序檢測拷貝數的改變。這種方法具有成本效益，可以同時分析多個樣本。

雖然它也能檢測到一些單核苷酸變化，但它不能檢測到所有的變化。與許多正在為兒童開發的液體活體組織切片不同，這種方法和其他研究人員的類似測試旨在識別多種類型的癌症。因此，由於上述因素，該市場有望在預測期內得到推動。

診斷癌症的新工具不斷發展，預計將推動液體活體組織切片市場成長

弗雷德-哈欽森癌症中心的計算生物學家Gavin Ha博士被授予2022年美國國家衛生研究院院長創新者獎。這筆150萬美元的五年撥款將支持哈的研究，即利用液體活體組織切片中的無細胞腫瘤DNA來收集用於癌症診斷、治療選擇和疾病監測的寶貴資訊。液體活體組織切片涉及分析血液樣本中的DNA痕跡，提供對腫瘤的分子洞察力。

雖然大多數液體活體組織切片策略側重於檢測與癌症相關的DNA序列變化，但哈氏採取了一種不同的方法，研究使DNA片段在血液中持續存在的因素，特別是研究DNA包裝蛋白提供的保護。我們細胞中的DNA被緊湊地包裝起來，而這種包裝在基因調控中起著作用。基因表達影響著癌細胞對治療的反應，它們的抵抗模式，以及它們轉化為不同癌細胞的潛力。

液體活體組織切片的技術挑戰和限制阻礙了全球液體活體組織切片市場的發展

液體活體組織切片技術面臨著各種技術挑戰，這些挑戰會限制其有效性並阻礙市場的成長。其中一些挑戰包括敏感性和特異性、標準化和可重複性。

此外，監管和報銷問題會阻礙液體活體組織切片測試的廣泛採用。這些挑戰包括監管部門的批准和報銷政策。因此，從上述因素來看，預計在預測期內，市場將受到阻礙。

COVID-19影響分析

COVID-19大流行病對液體活體組織切片市場產生了重大影響。在大流行期間，包括癌症篩查和診斷程序在內的常規醫療訪問有所減少。

因此，對液體活體組織切片測試的需求可能受到影響，因為這些測試通常被用作傳統組織活體組織切片的非侵入性替代品。病人就診和診斷測試的減少可能導致液體活體組織切片技術的總體採用和利用率下降。

此外，許多正在進行的與液體活體組織切片研究和開發有關的臨床試驗由於大流行病的影響而出現延誤或中斷。對病人招募的限制，對醫療設施的限制，以及對COVID-19管理資源的優先安排，導致了臨床試驗時間表的推遲或改變。這種研究活動的延遲會影響向市場推出新的液體活體組織切片技術和產品。

隨著大流行病的發展和醫療系統的適應，液體活體組織切片市場預計將恢復並繼續其成長軌跡，這是由技術、研究的進步和對個性化和無創癌症診斷的需求增加所推動的。

俄烏衝突分析

俄烏戰爭對各個領域都有影響，包括醫療行業和潛在的液體活體組織切片市場。這場戰爭對受影響地區的醫療基礎設施造成了實質性的中斷，特別是烏克蘭。醫療設施的損壞、醫療供應的短缺和醫療人員的遷移都會中斷醫療系統的常規運作。

由於資源被轉用於滿足更緊迫的醫療需求，這種中斷可能會影響許多診斷測試的可用性和可及性，包括液體活體組織切片。此外，戰爭及其經濟後果可能會改變醫療保健的支出和優先事項。由於預算有限，需要將資源分配給與戰爭有關的工作和衝突後的重建，可能會減少對醫療基礎設施、研究和發展的投資。

持續的衝突會阻礙受影響地區的研究和發展工作。對資金和資源的限制，加上不穩定的研究環境，會減緩有關液體活體組織切片技術的創新和科學突破的進展。此外，在衝突中，與國際夥伴合作和交流知識和專長可能面臨挑戰。

Market Overview

The Global Liquid Biopsy Market reached US$ 4.1 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 12.3 billion by 2030. The Global Liquid Biopsy Market is expected to exhibit a CAGR of 15.4% during the forecast period 2023-2030.

Liquid biopsy is a non-invasive diagnostic technique that analyzes biomarkers in body fluids, providing insights into various diseases such as cancer. It offers advantages over traditional tissue biopsies, such as easier sample collection and real-time disease monitoring.

Furthermore, the increasing prevalence of cancer globally, advancements in genomic research and technology, increasing adoption of minimally invasive diagnostic procedures, and rising potential for early detection and monitoring of diseases are expected to drive the market over the forecast period.

Market Dynamics

Rising Research in Liquid Biopsies on the Horizon for Children with Solid Cancers is Expected to Drive Liquid Biopsy Market Growth

According to National Cancer Institute Article 2023, researchers in the field of cancer are making advancements in the development of liquid biopsy tests, which have the potential to complement or even replace traditional tissue biopsies.

These tests analyze genetic and other material released by tumors into the bloodstream and other bodily fluids. Currently, liquid biopsies are being utilized to detect cancer-related genetic alterations and aid in treatment decision-making.

Scientists have expanded their research on liquid biopsies to include children with cancer, focusing on solid tumors such as Ewing sarcoma, osteosarcoma, and Wilms tumor (a kidney cancer). A recent study conducted by researchers from Children's Hospital Los Angeles (CHLA) and the University of Southern California has made progress in developing a liquid biopsy test specifically for pediatric cancer patients.

This test analyzes fragments of DNA found in blood samples and has shown promising results in diagnosing various types of solid tumors in children. The study, published in npj Precision Oncology, also indicates the potential of this test in assessing treatment response and detecting possible tumor recurrence following successful initial treatment.

The liquid biopsy test developed by the CHLA and USC researchers focuses on detecting copy number alterations using low-pass whole-genome sequencing. This method is cost-effective and can analyze multiple samples simultaneously.

While it can also detect some single-nucleotide changes, it cannot detect all of them. Unlike many liquid biopsies being developed for children, this approach and similar tests by other researchers aim to identify multiple types of cancer. Thus , the market is expected to drive over the forecast period due to the above factors.

Rising Development of New Tools in Diagnosing Cancer is Expected to Drive Liquid Biopsy Market Growth

Dr. Gavin Ha, a computational biologist at the Fred Hutchinson Cancer Center, has been awarded the 2022 National Institutes of Health Director's New Innovator Award. The $1.5 million five-year grant will support Ha's research in leveraging cell-free tumor DNA in liquid biopsies to gather valuable information for cancer diagnosis, treatment selection, and disease monitoring. Liquid biopsies, which involve analyzing DNA traces in blood samples, provide molecular insights into tumors.

While most liquid biopsy strategies focus on detecting cancer-associated changes in DNA sequence, Ha takes a different approach by investigating the factors that enable DNA fragments to persist in the bloodstream, specifically examining the protection provided by DNA packaging proteins. DNA in our cells is compactly packaged, and this packaging plays a role in gene regulation. Gene expression affects how cancer cells respond to treatments, their resistance patterns, and their potential to transform into different cancer cells.

Technical Challenges and Limitations in the Liquid Biopsy are Hampering the Growth of the Global Liquid Biopsy Market

Liquid biopsy techniques face various technical challenges that can limit their effectiveness and hinder the market growth. Some of these challenges include sensitivity and specificity, standardization, and reproducibility.

Besides, regulatory and reimbursement issues can hinder the widespread adoption of liquid biopsy tests. These challenges include regulatory approvals and reimbursement policies. Thus, from the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the liquid biopsy market. During the pandemic, there has been a decrease in routine healthcare visits, including cancer screenings and diagnostic procedures.

As a result, the demand for liquid biopsy tests may have been affected, as these tests are often used as non-invasive alternatives to traditional tissue biopsies. Reduced patient visits and diagnostic testing have likely resulted in a decline in the overall adoption and utilization of liquid biopsy technologies.

Moreover, many ongoing clinical trials related to liquid biopsy research and development have experienced delays or disruptions due to the pandemic. Restrictions on patient recruitment, limited access to healthcare facilities, and prioritization of resources for COVID-19 management have resulted in the postponement or alteration of clinical trial timelines. This delay in research activities can impact introducing new liquid biopsy technologies and products to the market.

As the pandemic evolves and healthcare systems adapt, the liquid biopsy market is expected to recover and continue its growth trajectory, driven by advancements in technology, research, and the increasing demand for personalized and non-invasive cancer diagnostics.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine war has had implications for various sectors, including the healthcare industry and potentially the liquid biopsy market. The war has caused substantial interruptions in impacted regions' healthcare infrastructure, particularly Ukraine. Damage to medical facilities, medical supply shortages, and the relocation of healthcare staff can all interrupt the routine operation of healthcare systems.

As resources are redirected to meet more pressing healthcare needs, this interruption may impact the availability and accessibility of numerous diagnostic tests, including liquid biopsy. Moreover, the war and its economic consequences can shift healthcare expenditures and priorities. With limited budgets and a need to allocate resources to war-related efforts and post-conflict rebuilding, there may be reduced investment in healthcare infrastructure, research, and development.

The ongoing conflict can obstruct research and development endeavors in the affected regions. Constraints on funding and resources, along with an unsettled research environment, can slow the progress of innovation and scientific breakthroughs concerning liquid biopsy technologies. Additionally, collaborating and exchanging knowledge and expertise with international partners may face challenges amidst the conflict.

Segment Analysis

The Global Liquid Biopsy Market is segmented based on circulating biomarkers, products & services, applications, technology, end user, and region.

The Kits & Reagents Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The kits & reagents segment accounted for the highest market stake, accounting for approximately 43.7% of the liquid biopsy market in 2022. Liquid biopsy kits and reagents are widely adopted worldwide. This is because liquid biopsy kits and reagents are the essential components required to collect and process samples for analysis.

These kits and reagents include specific reagents, enzymes, buffers, and other materials necessary for DNA or RNA extraction, amplification, and analysis. They are designed to provide researchers and healthcare professionals with standardized and reliable tools for liquid biopsy testing.

The increasing demand for non-invasive diagnostic methods and the growing awareness of liquid biopsy's potential in cancer detection and monitoring drives the adoption of liquid biopsy kits and reagents. These kits and reagents are readily available from various manufacturers and suppliers, making them accessible to laboratories and research institutions worldwide. Thus, owing to the above factors, the market is expected to hold the largest market share in the forecast period.

Geographical Analysis

The North American Region is Dominating the Global Liquid Biopsy Market

North America is expected to dominate the nootropics market, accounting for around 38.9%. Higher investments and numerous biotechnology businesses producing the tests, high cancer prevalence, rapid technological advancements, increasing regulatory approvals, and growing government initiatives dominate the North American region.

For instance, on May 29, 2023, Guardant Health, Inc. announced that Singapore's Health Sciences Authority (HSA) had granted regulatory approval for Guardant360 CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with TAGRISSO (osimertinib).

Furthermore, on March 22, 2023, Droplet Biosciences, a biotechnology company specializing in liquid biopsy technologies, recently secured an $8 million seed investment to develop its lymph-based liquid biopsy platform further.

The investment will support the company's efforts in advancing its proprietary technology and expanding its cancer detection and monitoring capabilities. Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Exosome Sciences Inc., Grail Inc, Guardant Health, Thermo Fisher Scientific Inc., Inivata Ltd, Illumina Inc, LungLife AI Inc, and Qiagen NV among others.

Why Purchase the Report?

To visualize the Global Liquid Biopsy Market segmentation based on the circulating biomarker, product & services, application, technology, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous liquid biopsy market-level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Liquid Biopsy Market Report Would Provide Approximately 77 Tables, 77 Figures And 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Circulating Biomarker
3.2. Snippet by Product & Services
3.3. Snippet by Application
3.4. Snippet by Technology
3.5. Snippet by End User
3.6. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Research in Liquid Biopsies on the Horizon for Children with Solid Cancers
  - 4.1.1.2. Rising Development of New Tools in Diagnosing Cancer
- 4.1.2. Restraints
  - 4.1.2.1. Technical Challenges and Limitations in the Liquid Biopsy
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing Research Collaborations
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Circulating Biomarker

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 8.1.2. Market Attractiveness Index, By Circulating Biomarker
8.2. Circulating Tumor Cells*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Circulating Tumor DNA (ctDNA)
8.4. Cell-free DNA (cfDNA)
8.5. Extracellular Vesicles

9. By Product & Services

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
- 9.1.2. Market Attractiveness Index, By Product & Services
9.2. Kits & Reagents*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Instruments
9.4. Services

10. By Application

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.1.2. Market Attractiveness Index, By Application
10.2. Cancer Applications*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.2.3. Breast Cancer
- 10.2.4. Colorectal Cancer
- 10.2.5. Lung Cancer
- 10.2.6. Prostate Cancer
- 10.2.7. Liver Cancer
- 10.2.8. Other
10.3. Non-Cancer Applications
- 10.3.1. Non-Invasive Prenatal Testing (NIPT)
- 10.3.2. Organ Transplantations
- 10.3.3. Infectious Disease Testing

11. By Technology

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.1.2. Market Attractiveness Index, By Technology
11.2. Multi-gene-parallel Analysis (NGS)*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Single Gene Analysis (PCR Microarrays)

12. By End User

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.1.2. Market Attractiveness Index, By End User

12.2. Hospitals and Physician Laboratories*
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Research Centers
12.4. Others

13. By Region

13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 13.2.8.1. The U.S.
  - 13.2.8.2. Canada
  - 13.2.8.3. Mexico
13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 13.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 13.3.8.1. Germany
  - 13.3.8.2. The U.K.
  - 13.3.8.3. France
  - 13.3.8.4. Italy
  - 13.3.8.5. Spain
  - 13.3.8.6. Rest of Europe
13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 13.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 13.4.8.1. Brazil
  - 13.4.8.2. Argentina
  - 13.4.8.3. Rest of South America
13.5. Asia Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 13.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 13.5.8.1. China
  - 13.5.8.2. India
  - 13.5.8.3. Japan
  - 13.5.8.4. Australia
  - 13.5.8.5. Rest of Asia Pacific
13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
- 13.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
- 13.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 13.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
- 13.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies

15. Company Profiles

15.1. Bio-Rad Laboratories*
- 15.1.1. Company Overview
- 15.1.2. Product Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
15.2. F. Hoffmann-La Roche AG
15.3. Exosome Sciences Inc.
15.4. Grail Inc
15.5. Guardant Health
15.6. Thermo Fisher Scientific Inc.
15.7. Inivata Ltd
15.8. Illumina Inc
15.9. LungLife AI Inc
15.10. Qiagen NV

LIST NOT EXHAUSTIVE